Potent HCV NS3 Protease Inhibition by a Water-Soluble Phyllanthin Congener

被引:3
|
作者
Reddy, Uma B. [2 ]
Tandon, Himani [1 ]
Pradhan, Manoj K. [4 ]
Adhikesavan, Harikrishnan [4 ]
Srinivasan, Narayanaswamy [1 ]
Das, Saumitra [2 ,3 ]
Jayaraman, Narayanaswamy [4 ]
机构
[1] Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India
[2] Indian Inst Sci, Microbiol & Cell Biol, Bangalore 560012, Karnataka, India
[3] Natl Inst Biomed Genom, Kalyani 741251, W Bengal, India
[4] Indian Inst Sci, Dept Organ Chem, Bangalore 560012, Karnataka, India
来源
ACS OMEGA | 2020年 / 5卷 / 20期
关键词
HEPATITIS-C-VIRUS; CRYSTAL-STRUCTURES; SERINE-PROTEASE; RNA REPLICATION; AMARUS; PROTEINASE; RESISTANCE; CLEAVAGE; FITNESS; ASSAY;
D O I
10.1021/acsomega.0c00786
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
NS3/4A protease of hepatitis C virus (HCV) plays an important role in viral RNA replication. A 1,4-diphenylbutanedicarboxylic acid derivative, namely, phyllanthin, extracted from the leaf of a herbal plant, Phyllanthus amarus, inhibits HCV NS3/4A protease and replication activities. However, the reduced aqueous solubility, high toxicity, and poor oral bioavailability are major impediments with phyllanthin. We herein present a design approach to generate phyllanthin congeners in order to potentiate inhibition activity against protease. The phyllanthin congeners were synthesized by chemical methods and subjected to systematic biological studies. One of the congeners, annotated as D8, is identified as a novel and potent inhibitor of the HCV-NS3/4Aprotease activity in vitro and the viral RNA replication in cell culture. Structural analysis using the computational-based docking approach demonstrated important noncovalent interactions between D8 and the catalytic residues of the viral protease. Furthermore, D8 was found to be significantly nontoxic in cell culture. More importantly, oral administration of D8 in BALB/c mice proved its better tolerability and bioavailability, as compared to native phyllanthin. Taken together, this study reveals a promising candidate for developing anti-HCV therapeutics to control HCV-induced liver diseases.
引用
收藏
页码:11553 / 11562
页数:10
相关论文
共 50 条
  • [21] Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings
    Chen, Kevin X.
    Vibulbhan, Bancha
    Yang, Weiying
    Nair, Latha G.
    Tong, Xiao
    Cheng, Kuo-Chi
    Njoroge, F. George
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (04) : 1105 - 1109
  • [22] Engineered Toxins "Zymoxins'' Are Activated by the HCV NS3 Protease by Removal of an Inhibitory Protein Domain
    Shapira, Assaf
    Gal-Tanamy, Meital
    Nahary, Limor
    Litvak-Greenfeld, Dana
    Zemel, Romy
    Tur-Kaspa, Ran
    Benhar, Itai
    PLOS ONE, 2011, 6 (01):
  • [23] Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir
    Timm, Jennifer
    Kosovrasti, Klajdi
    Henes, Mina
    Leidner, Florian
    Hou, Shurong
    Ali, Akbar
    Yilmaz, Nese Kurt
    Schiffer, Celia A.
    ACS CHEMICAL BIOLOGY, 2020, 15 (02) : 342 - 352
  • [24] TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection
    Tsantrizos, Youla S.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (08) : 871 - 881
  • [25] NS3 protease of genotype 3 subtype h HCV identified in southeastern France
    Colson, Philippe
    Gayet, Stephane
    Gerolami, Rene
    ANTIVIRAL THERAPY, 2011, 16 (04) : 615 - 619
  • [26] Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease
    Soumana, Djade I.
    Ali, Akbar
    Schiffer, Celia A.
    ACS CHEMICAL BIOLOGY, 2014, 9 (11) : 2485 - 2490
  • [27] Designing and molecular docking of cyclic peptides against HCV NS3 protease
    Masoud, Muhammad Shareef
    Bukhari, Shazia Anwer
    Qasim, Muhammad
    Naqvi, Syed Ali Raza
    Ashfaq, Usman A.
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 30 (05) : 1965 - 1969
  • [28] Computational Modelling in Studies for Hepatitis C Virus (HCV) NS3 Protease
    Mukhametov, Azat
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (12) : 1351 - 1361
  • [29] The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease
    Monteagudo, E.
    Fonsi, M.
    Chu, X.
    Bleasby, K.
    Evers, R.
    Pucci, V.
    Orsale, M. V.
    Cianetti, S.
    Ferrara, M.
    Harper, S.
    Laufer, R.
    Rowley, M.
    Summa, V.
    XENOBIOTICA, 2010, 40 (12) : 826 - 839
  • [30] Treatment of HCV infection with the novel NS3/4A protease inhibitors
    De Luca, Andrea
    Bianco, Claudia
    Rossetti, Barbara
    CURRENT OPINION IN PHARMACOLOGY, 2014, 18 : 9 - 17